reports
- Jean Danjou
- Jean Danjou
- Benoit Valleaux
- Roland Pfaender
- MBA
- CFA
- CCRA
Phoenix Group : Strong cash flow generation but solvency lower than ex...
>Strong cash flow generation - Phoenix Group released its H1 2024 results yesterday morning. Premium volumes on annuity products dropped to £ 1.7bn (vs £ 3.2bn in H1 2023), with £ 0.4bn stemming from BPA down sharply on H1 2023, but the group indicated that transactions equating to an additional £ 2.2bn are currently under way. Phoenix Group continued to develop its positions in the Pensions and Savings market, with an increase of 9% in H1 in assets under administrati...
- Benoit Valleaux
- Roland Pfaender
- MBA
- CFA
- CCRA
Phoenix group : Forte génération de cash-flow mais solvabilité inférie...
>Forte progression de la génération de cash-flow - Phoenix Group a publié hier matin son RN du S1 2024. Le volume de primes sur les produits annuity a baissé à 1.7 Md£ (vs 3.2 Md£ au S1 2023), dont 0.4 Md£ provenant des BPA en net recul par rapport au S1 2023, mais le groupe indique que des opérations représentant 2.2 Md£ supplémentaires sont actuellement en cours. Phoenix Group poursuit son développement sur le marché Pensions and Savings, avec une hausse de 9% au S1...
AstraZeneca: 1 director
A director at AstraZeneca bought 2,000 shares at 11,793p and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
AstraZeneca : Une survie globale dans TROPION Lung01 peu concluante
>Marginalement mieux que docetaxel - Hier soir, AZN a présenté de nouvelles données de son célèbre essai TROPION-Lung01 évaluant Dato-DXd par rapport à la chimiothérapie chez des patients adultes atteints d'un cancer du poumon non à petites cellules (NSCLC) localement avancé ou métastatique non squameux et ayant reçu au moins une ligne de traitement antérieure.Dans l'ensemble de la population de l'essai, les résultats de la survie globale sont en faveur de Dato’ ...
- Damien Choplain
- Martial Descoutures
AstraZeneca : Overall survival in TROPION Lung01 fairly inconclusive
>Marginally better than docetaxel - Yesterday evening, AstraZeneca presented new data for its renowned TROPION-Lung01 study, evaluating Dato-DXd versus chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) and having already received at least one line of previous treatment.For the study population as a whole, the results for overall survival were in favour of Dato’ versus docetaxel (12.9 months vs 11.8 months), a...
- Benoit Valleaux
- Roland Pfaender
- MBA
- CFA
- CCRA
Phoenix Group : Gradual growth in operating cash flow generation expec...
>Gradual operating cash flow generation growth - Phoenix Group is due to report its H1 2024 results on 16 September. We forecast total cash generation of £ 745m (-17.0% vs a comparison base of £ 898m in H1 2023), close to the consensus (£ 739m). The group presented a new metric at the presentation of its full-year results, namely operating cash generation, which equates to a sustainable level of surplus capital generation under Solvency 2 from the insurance subsidiari...
- Benoit Valleaux
- Roland Pfaender
- MBA
- CFA
- CCRA
Phoenix group : Croissance graduelle attendue de la génération opérati...
>Une hausse graduelle de la génération de CF opérationnel - Phoenix Group publiera son RN du S1 2024 le 16 septembre prochain. Nous prévoyons une génération de cash-flow totale de 745 M£ (-17.0% vs une base de comparaison de 898 M£ au S1 2023) proche du consensus (739 M£). Rappelons que le groupe a présenté une nouvelle métrique lors de la présentation de son résultat annuel, à savoir la génération de cash-flow opérationnelle (Operating Cash Génération), qui correspon...
- Damien Choplain
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/03/2024
After a stress episode in the first few days of the month, the equity markets finished August on a gain. US markets ended slightly ahead of Europe, thanks notably to the latest good US GDP numbers, but this performance is erased by the strong rise of the euro. The main driver was short rates falling in anticipation of rate cuts by central banks, with 2-year rates coming close to 10-year rates in the US and Europe. Tech stocks took a hit but less so than in July, and the two worst per...
- Damien Choplain
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 03/09/2024
Après leur stress tout début août, les marchés actions finissent le mois dans le vert. Les marchés américains terminent légèrement devant l’Europe, notamment grâce aux derniers bons chiffres du PIB USA, mais cette performance est effacée par la forte remontée de l’euro. Ce sont surtout les taux courts qui ont reculé, anticipant des baisses de taux par les banques centrales, le 2 ans revenant proche du 10 ans aux USA comme en Europe. Les valeurs technologiques ont souffert mais moins q...
- Damien Choplain
ODDO : IRA : rabais de la première liste en ligne avec nos attentes
>Discount de la première liste Medicare enfin dévoilé (-66% en médiane) - Le 15 août dernier, l’administration Biden-Harris a officiellement communiqué le rabais qui sera appliqué aux 10 médicaments (voir tableau en deuxième page) de la première liste établie par Medicare dans le cadre de l’IRA. Il ressort donc de ces négociations un discount appliqué sur le list price allant de -38% (Imbruvica ; oncologie) à -79% (Januvia ; diabète) avec une médiane à -66%, ce qui d...
- Damien Choplain
ODDO : IRA: discount on the first list in line with our forecasts
>Discount for the first Medicare list finally announced (median of -66%) - On 15 August, the Biden-Harris administration officially announced the discount that will be applied to the 10 drugs (see the list on page 2) of the first list set out by Medicare within the IRA framework. The result of the negotiations is an applied discount to the list price ranging from -38% (Imbruvica, oncology) to -79% (Januvia, diabetes) with a median of -66%, which should generate savin...
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- Jerôme Bodin
IPS IPSOS
SOP SOPRA STERIA GROUP SA
ROG ROCHE HOLDING LTD
EO FAURECIA SA
NOVN NOVARTIS AG
CEN GROUPE CRIT SA
SDG SYNERGIE SA
MERY MERCIALYS SA
VIV VIVENDI SE
AUB AUBAY SA
NRG NRJ GROUP SA
FNAC FNAC DARTY SA
HOT HOCHTIEF AG
ACX ACERINOX SA
BAMNB KONINKLIJKE BAM GROEP NV
SAN SANOFI
ELIS ELIS SA
MAREL MAREL HF.
VASTN VASTNED RETAIL NV
VID VIDRALA SA
AIXA AIXTRON SE
ARCAD ARCADIS NV
ALVIV VISIATIV SA
AALB AALBERTS N.V.
CARM CARMILA SAS
LOG COMPANIA DE DISTRIBUCION INTEGRAL LOGISTA HOLDINGS S.A.
WAF SILTRONIC AG
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ARG ARGAN SA
SIFG SIF HOLDING NV
ASS APPLUS SERVICES S.A.
VLTSA VOLTALIA
AZN ASTRAZENECA PLC
ECONT ECONOCOM GROUP SE CLASS D
BFSA BEFESA SA
PWG PRODWAYS GROUP SA
VOS VOSSLOH AG
WAVE WAVESTONE SA
S30 SOLUTIONS 30 SE
VRLA VERALLIA SAS
TCH TECHNICOLOR SA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
FUR FUGRO NV
FORSE FORSEE POWER SA
MTRK MOTORK LTD
ALVGO VOGO SA
IVG IVECO GROUP
SPM SAIPEM S.P.A.
GSK GSK PLC
AF AIR FRANCE - KLM
NOVO B NOVO NORDISK A/S
- Jerôme Bodin
FP TOTAL SE
AC ACCOR SA
GET GETLINK SE
IPN IPSEN SA
EQNR EQUINOR ASA
JMT JERONIMO MARTINS SGPS S.A.
CA CARREFOUR SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
BNP BNP PARIBAS SA CLASS A
RNO RENAULT SA
ROG ROCHE HOLDING LTD
SK SEB SA
SSAB A SSAB AB CLASS A
NOVN NOVARTIS AG
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
CPG COMPASS GROUP PLC
NESN NESTLE S.A.
VIV VIVENDI SE
NRG NRJ GROUP SA
RF EURAZEO SA
KER KERING SA
ELE ENDESA S.A.
SAN SANOFI
VER VERBUND AG CLASS A
EZJ EASYJET PLC
REP REPSOL SA
SOI SOITEC SA
SIX2 SIXT SE
MOCORP METSO OUTOTEC OYJ
MONC MONCLER SPA
IBE IBERDROLA SA
AZN BANCO SANTANDER S.A.
VOD ASTRAZENECA PLC
STM VODAFONE GROUP PLC
BESI STMICROELECTRONICS NV
ULA BE SEMICONDUCTOR INDUSTRIES N.V.
ERF UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
STLA EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
UMG STELLANTIS N.V.
DSY UNIVERSAL MUSIC GROUP NV
ML DASSAULT SYSTEMES SA
GSK COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 GSK PLC
SGSN DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
NOVO B SGS SA
NOVO NORDISK A/S
- Jerôme Bodin
FP TOTAL SE
AC ACCOR SA
GET GETLINK SE
IPN IPSEN SA
EQNR EQUINOR ASA
JMT JERONIMO MARTINS SGPS S.A.
CA CARREFOUR SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
BNP BNP PARIBAS SA CLASS A
RNO RENAULT SA
ROG ROCHE HOLDING LTD
SK SEB SA
SSAB A SSAB AB CLASS A
NOVN NOVARTIS AG
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
CPG COMPASS GROUP PLC
NESN NESTLE S.A.
VIV VIVENDI SE
NRG NRJ GROUP SA
RF EURAZEO SA
KER KERING SA
ELE ENDESA S.A.
VER SANOFI
EZJ VERBUND AG CLASS A
REP EASYJET PLC
SOI REPSOL SA
SIX2 SOITEC SA
MOCORP SIXT SE
MONC METSO OUTOTEC OYJ
IBE MONCLER SPA
SAN IBERDROLA SA
AZN BANCO SANTANDER S.A.
VOD ASTRAZENECA PLC
STM VODAFONE GROUP PLC
BESI STMICROELECTRONICS NV
ULA BE SEMICONDUCTOR INDUSTRIES N.V.
ERF UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
STLA EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
UMG STELLANTIS N.V.
DSY UNIVERSAL MUSIC GROUP NV
ML DASSAULT SYSTEMES SA
GSK COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 GSK PLC
SGSN DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
NOVO B SGS SA
NOVO NORDISK A/S
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.